Reevaluate CAR Targets for T cell Malignancies

Reevaluate CAR Targets for T cell Malignancies

Chimeric antigen receptor Tcell (CART) therapy has been prosperous in the treatment of patients with various types of B-cell malignancies. However, this type of therapy has faced serious hindrances in combating Tcell neoplasms. Such as a lack of Tcell tumor-specific targeting antigens, Tcell aplasia so on. As a leading manufacturer of recombinant proteins to support the development of CART cell therapy, ACROBiosystems can provide a wide series of targets including covering different species and fluorescent labeling types that can accelerate your Tcell malignancies research. T-cell antigen CD7 , T-cell antigen CD7,GP40,CD7,TP41,CD7 Molecule,T-Cell Leukemia Antigen,T-Cell Surface Antigen Leu-9,CD7 Antigen (P41),P41 Protein,CD7 Antigen,LEU-9,Tp40,Antigens, CD7,T-cell surface antigen CD4 , CD4mut,CD4 Antigens,T-cell surface antigen T4/Leu-3,T-cell surface glycoprotein CD4,CD4,CD4 Molecule,CD4 Antigen (P55),CD4 Receptor,CD4 Antigen , T-cell surface glycoprotein CD5 , Epididymis Secretory Sperm Binding Protein,CD5,Lymphocyte antigen T1/Leu-1,T-cell surface glycoprotein CD5,CD5 Molecule,CD5 Antigen (P56-62),LEU1,CD5 Antigen,T1,CD5 Antigens